John Libbey Eurotext

European Journal of Dermatology

MENU

Dermatological adverse events with taxane chemotherapy Volume 26, numéro 5, September-October 2016

Illustrations

  • Figure 1
  • Figure 2
  • Figure 3
  • Figure 4
  • Figure 5
  • Figure 6
  • Figure 7
  • Figure 8
  • Figure 9
  • Figure 10
  • Figure 11
  • Figure 12
  • Figure 13
  • Figure 14
  • Figure 15
  • Figure 16
  • Figure 17

Tableaux

Auteurs
1 Departments of Oncodermatology and Clinical Research,
Institut Claudius Regaud, Institut Universitaire du Cancer,
Toulouse Oncopole, France
2 Department of Dermatology,
Dana–Farber/ Brigham and Women's Cancer Center/ Harvard Medical School,
Boston, MA, USA
3 Department of Oncology,
Institut Claudius Regaud,
Institut Universitaire du Cancer,
Toulouse Oncopole, France
4 Dermatology Service,
Memorial Sloan Kettering Cancer Center,
New York, NY, USA
5 Department of Oral Medicine,
Institut Claudius Regaud,
Institut Universitaire du Cancer,
Toulouse Oncopole, France
* Reprints

Paclitaxel and docetaxel belong to the taxane class of cytotoxic agents, and are among the most commonly prescribed chemotherapeutic agents in oncology, especially in gynaecological cancers. Paclitaxel is a natural extract derived from the bark of the pacific yew tree (Taxus brevifolia)thatbecame commercially available in 1992. On the other hand, docetaxel is a semisynthetic analogue of paclitaxel synthesised from the needles of the European yew tree (Taxus baccata). Both drugs act as antimicrotubule [...]